Table 2.
Undergoing multinational and national projects with their settings.
| Country | Number of Participants | Type of Study | Stage | Drug | Dose Concentration | Estimation Completion | Identifier | Reference |
|---|---|---|---|---|---|---|---|---|
| Spain n = 1 center |
n = 300 | Interventional (Randomized) |
Phase 3 | follitropin delta follitropin alfa |
5 µg—min dose; 20 µg—max dose; 5 µg adjustments 225 IU; 75 IU adjustments; 75 IU—min; 300 IU—max; |
2023 | NCT05263388 | [27] |
| Germany n = 1 center |
n = 300 | Observational (Cohort) |
- | follitropin delta | NS | 2024 | NCT05173597 | [28] |
| Denmark n = 1 center |
n = 200 | Observational (Cohort) |
- | follitropin delta | NS | 2024 | NCT05499052 | [29] |
| India n = 11 centers |
n = 220 | Interventional (Randomized) |
Phase 3 | follitropin delta follitropin alfa |
12 µg—max 150 IU; 75 IU adjustments, up to 450 IU |
2024 | NCT04773353 | [30] |
NS—not specified.